Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 12, 2016 10:51:00 GMT -5
hope its material enough to the tune of 40 mil to last 1 qtr and not like 1 mil like dangling a carrot I would love 40 million but if we just got 250,000 I am sure its going to be a small mile stone. It would be nice if it was something large so the street would take rls serious What did you make of the SNY slide? nuetral - as with Mannkind nothing goes like planned - if SNY can part with 40 mil to extend the runway - it would be great
|
|
|
Post by rockstarrick on May 12, 2016 10:55:41 GMT -5
Matt was pretty nervous. His tempo was uneven and shaky. But he does have a good handle on the issues facing the company and the technical details. It's clear to me that the company is fighting an uphill battle with one hand tied behind its back. Even with the new funding the runway is too short - it'll take us to end of the year. It appears all is dependent on a successful re-launch of Afrezza. I have a hard time believing that demonstrated success can occur in such a short time frame. That's pretty thin ice. Also I'm concerned that INTL deals have not come to fruition. I believe the company was counting on upfront money from those deals. My guess is they will only happen if and when Afrezza has been proven in the re-launch. I wouldn't look for that kind of income for at least a year. Lots of information here but nothing we haven't already heard. All in all, not terrible like Monday but far from earth shattering. I'm a HOLD, definitely not a buy. That's my 2cents. Yes, Matt said the net cash they raised with the offering would get them through December, but also said they were looking at options that could make the cash last a bit longer. He also said they would be getting another milestone payment from RLS, and said we would be hearing more about RLS this year. He didn't sound nervous to me, he sounded rushed, he tried to speak quickly so there would be time for questions, there was only enough time to answer 1 question before time ran out.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 12, 2016 10:56:47 GMT -5
Matt was pretty nervous. His tempo was uneven and shaky. But he does have a good handle on the issues facing the company and the technical details. It's clear to me that the company is fighting an uphill battle with one hand tied behind its back. Even with the new funding the runway is too short - it'll take us to end of the year. It appears all is dependent on a successful re-launch of Afrezza. I have a hard time believing that demonstrated success can occur in such a short time frame. That's pretty thin ice. Also I'm concerned that INTL deals have not come to fruition. I believe the company was counting on upfront money from those deals. My guess is they will only happen if and when Afrezza has been proven in the re-launch. I wouldn't look for that kind of income for at least a year. Lots of information here but nothing we haven't already heard. All in all, not terrible like Monday but far from earth shattering. I'm a HOLD, definitely not a buy. That's my 2cents. I think he was also pretty exhausted. My guess is he has been burning the oil 7 days a week and who knows if he was up all night finalizing the financing deal. Plus, given his recent eye surgery he still cannot be running at 100% nor would I expect him to be. People have different views on him but he is a ballbuster. Its going to be a very interesting balance of 2016. We should be able to get a bit of traction. When Matt referred to input from key doctors there are some significant ones that are Afrezza fans. They alone have the potential to move the needle in terms of Rx counts.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 12, 2016 11:02:12 GMT -5
Matt was pretty nervous. His tempo was uneven and shaky. But he does have a good handle on the issues facing the company and the technical details. It's clear to me that the company is fighting an uphill battle with one hand tied behind its back. Even with the new funding the runway is too short - it'll take us to end of the year. It appears all is dependent on a successful re-launch of Afrezza. I have a hard time believing that demonstrated success can occur in such a short time frame. That's pretty thin ice. Also I'm concerned that INTL deals have not come to fruition. I believe the company was counting on upfront money from those deals. My guess is they will only happen if and when Afrezza has been proven in the re-launch. I wouldn't look for that kind of income for at least a year. Lots of information here but nothing we haven't already heard. All in all, not terrible like Monday but far from earth shattering. I'm a HOLD, definitely not a buy. That's my 2cents. I think he was also pretty exhausted. My guess is he has been burning the oil 7 days a week and who knows if he was up all night finalizing the financing deal. Plus, given his recent eye surgery he still cannot be running at 100% nor would I expect him to be. People have different views on him but he is a ballbuster. Its going to be a very interesting balance of 2016. We should be able to get a bit of traction. When Matt referred to input from key doctors there are some significant ones that are Afrezza fans. They alone have the potential to move the needle in terms of Rx counts. whats stopping them to do now? its not like mannkind is coming with next version with Afrezza
|
|
|
Post by rockstarrick on May 12, 2016 11:06:48 GMT -5
Matt also stated that the offering was sold to select investors so it wouldn't have a negative affect on shareholders. Not his exact words, I'm shooting from memory, but I'm fairly sure this is an accurate statement.
|
|
|
Post by rch51 on May 12, 2016 11:07:07 GMT -5
I think he was also pretty exhausted. My guess is he has been burning the oil 7 days a week and who knows if he was up all night finalizing the financing deal. Plus, given his recent eye surgery he still cannot be running at 100% nor would I expect him to be. People have different views on him but he is a ballbuster. Its going to be a very interesting balance of 2016. We should be able to get a bit of traction. When Matt referred to input from key doctors there are some significant ones that are Afrezza fans. They alone have the potential to move the needle in terms of Rx counts. whats stopping them to do now? its not like mannkind is coming with next version with Afrezza Yes, he did sound pretty tired. I think that Matt is doing an astonishing job given the hurdles he has to negotiate. I wish I had a little more bone to chew on but after all these years I'm kind of used to the uncertainty. If we are successful in pulling this re-launch off it truly will be an epic story.
|
|
|
Post by therealisaching on May 12, 2016 11:11:31 GMT -5
Replay is now available for those who missed the webcast
|
|
|
Post by rockstarrick on May 12, 2016 11:14:14 GMT -5
I think he was also pretty exhausted. My guess is he has been burning the oil 7 days a week and who knows if he was up all night finalizing the financing deal. Plus, given his recent eye surgery he still cannot be running at 100% nor would I expect him to be. People have different views on him but he is a ballbuster. Its going to be a very interesting balance of 2016. We should be able to get a bit of traction. When Matt referred to input from key doctors there are some significant ones that are Afrezza fans. They alone have the potential to move the needle in terms of Rx counts. whats stopping them to do now? its not like mannkind is coming with next version with Afrezza Nothing is stopping them, they are starting with nursing educators this month, producing different options of samples so they better fit the needs of the different patients, and the sales force will be hitting the pavement very soon, next month I believe. There has to be organization and training for these sales people, you can't just give them an afrezza t-shirt and throw them to the wolves. Matt said more than once, thing were coming together at record pace, right ??
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 12, 2016 11:22:14 GMT -5
whats stopping them to do now? its not like mannkind is coming with next version with Afrezza Nothing is stopping them, they are starting with nursing educators this month, producing different options of samples so they better fit the needs of the different patients, and the sales force will be hitting the pavement very soon, next month I believe. There has to be organization and training for these sales people, you can't just give them an afrezza t-shirt and throw them to the wolves. Matt said more than once, thing were coming together at record pace, right ?? you are misreading my post. Me reply of "whats stopping them to do now? its not like mannkind is coming with next version with Afrezza" was to question Scott's comment "When Matt referred to input from key doctors there are some significant ones that are Afrezza fans. They alone have the potential to move the needle in terms of Rx counts. "
|
|
|
Post by uhitit on May 12, 2016 11:39:40 GMT -5
Yes overall a good presentation. The key number to watch are the subscriptions he said. I believe he has the guys To execute the plan for this year.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 12, 2016 11:42:44 GMT -5
Nothing is stopping them, they are starting with nursing educators this month, producing different options of samples so they better fit the needs of the different patients, and the sales force will be hitting the pavement very soon, next month I believe. There has to be organization and training for these sales people, you can't just give them an afrezza t-shirt and throw them to the wolves. Matt said more than once, thing were coming together at record pace, right ?? you are misreading my post. Me reply of "whats stopping them to do now? its not like mannkind is coming with next version with Afrezza" was to question Scott's comment "When Matt referred to input from key doctors there are some significant ones that are Afrezza fans. They alone have the potential to move the needle in terms of Rx counts. " They want the nurse educators up and running so that the nurse educator can meet with patients at the doctors office and do a hands on training with the patient. It is going to be a value added service, reduces patient drop off rate, saves doctor & doctor staff time and helps patient to "dial it in" quickly and with minimal patient frustration. Nurse Educators aka: DNEs aka: Diabetes Nurse Educators may also help with the prior authorization but this is a guess on my part. They also act as a second set of eyes and ears and with greater clinical knowledge than most reps DNEs bring their own form of credibility to the physician and staff. Smart move to get the DNEs out a month before the reps. Shows commitment to docs and confidence in Afrezza.
|
|
|
Post by bradleysbest on May 12, 2016 11:46:34 GMT -5
I am interested to know how much of the sales force has been hired already including the national & regional directors?
|
|
|
Post by rockstarrick on May 12, 2016 11:46:35 GMT -5
Nothing is stopping them, they are starting with nursing educators this month, producing different options of samples so they better fit the needs of the different patients, and the sales force will be hitting the pavement very soon, next month I believe. There has to be organization and training for these sales people, you can't just give them an afrezza t-shirt and throw them to the wolves. Matt said more than once, thing were coming together at record pace, right ?? you are misreading my post. Me reply of "whats stopping them to do now? its not like mannkind is coming with next version with Afrezza" was to question Scott's comment "When Matt referred to input from key doctors there are some significant ones that are Afrezza fans. They alone have the potential to move the needle in terms of Rx counts. " Sorry about that, you are correct, I misunderstood you. sincere apologies
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 12, 2016 11:47:44 GMT -5
you are misreading my post. Me reply of "whats stopping them to do now? its not like mannkind is coming with next version with Afrezza" was to question Scott's comment "When Matt referred to input from key doctors there are some significant ones that are Afrezza fans. They alone have the potential to move the needle in terms of Rx counts. " They want the nurse educators up and running so that the nurse educator can meet with patients at the doctors office and do a hands on training with the patient. It is going to be a value added service, reduces patient drop off rate, saves doctor & doctor staff time and helps patient to "dial it in" quickly and with minimal patient frustration. Nurse Educators aka: DNEs aka: Diabetes Nurse Educators may also help with the prior authorization but this is a guess on my part. They also act as a second set of eyes and ears and with greater clinical knowledge than most reps DNEs bring their own form of credibility to the physician and staff. Smart move to get the DNEs out a month before the reps. Shows commitment to docs and confidence in Afrezza. I thought nurse educators were call in ( only telephone support) and then for community gatherings - Will they be making doctor office visits too? I need to look more into this job posting publicis.taleo.net/careersection/publicis_touchpoint_solutions_career_section/jobdetail.ftl?job=TOU011017&iniurl.src=JB-11000publicis.taleo.net/careersection/publicis_touchpoint_solutions_career_section/jobsearch.ftl?iniurl.src=JB-11000
|
|
|
Post by inittowinit on May 12, 2016 11:51:24 GMT -5
Not enough time. Always needing money, never making any real money.
To bad, I'm will reduce half my holdings. Pennies on the dollar.
These guys are part of what's wrong with the Street. They do not have time or capital to realize this plan to fruation....Something doesn't add up here and I'm done playing kick the can. GLTAL. Alot of folks got burned here....
|
|